{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:28:19Z","timestamp":1789363699379,"version":"build-2803163510"},"reference-count":40,"publisher":"American Diabetes Association","issue":"8","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>A gene mutation of the Wnt\/\u03b2-catenin signaling cascade is present in rare patients with the insulin resistance syndrome. Sclerostin is a circulating peptide inhibiting Wnt\/\u03b2-catenin signaling. Our aims were to evaluate serum sclerostin in subjects with prediabetes and to analyze its relationship with insulin resistance and \u03b2-cell function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>We performed a cross-sectional study including 43 healthy normal glucose-tolerant (NGT) individuals and 79 individuals with impaired glucose regulation (IGR), which included subjects with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and combined IFG-IGT, undergoing oral glucose tolerance test (OGTT) and dual-energy X-ray absorptiometry. A subgroup of 18 with NGT and 30 with IGR also underwent a euglycemic\u2013hyperinsulinemic clamp with tracer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Sclerostin levels were higher in IGR compared with NGT (50.8 \u00b1 2.4 vs. 38.7 \u00b1 2.3 pmol\/L; P = 0.01), positively correlated with HOMA-insulin resistance (IR) (r = 0.62; P &amp;lt; 0.001), and negatively correlated with insulin-mediated total body glucose disposal (r = \u22120.40; P &amp;lt; 0.001). Fasting endogenous glucose production (EGP) and hepatic and adipose tissue insulin resistance indexes were positively correlated with sclerostin levels (r = 0.48, r = 0.62, and r = 0.61, respectively; P &amp;lt; 0.001). Fasting and OGTT insulin clearance were inversely correlated with sclerostin serum levels (r = \u22120.52 and r = \u22120.44, respectively; both P &amp;lt; 0.001). Sclerostin levels were not correlated with \u03b2-cell function parameters. In multiple linear regression analysis, the addition of sclerostin levels to the traditional risk factors for insulin resistance improved the r2 associated with HOMA-IR (r2 change: 0.055; F change: 28.893; P = 0.001) and insulin-mediated total body glucose disposal (r2 change: 0.059; F change: 4.938; P = 0.033).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Sclerostin levels are increased in individuals with prediabetes and correlated with insulin resistance in skeletal muscle, liver, and adipose tissue. The correlation between sclerostin and insulin clearance at fasting state and during OGTT is novel; thus, studies are needed to explore the potential causal relationship.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc14-2989","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T22:20:40Z","timestamp":1434579640000},"page":"1509-1517","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":122,"title":["Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism"],"prefix":"10.2337","volume":"38","author":[{"given":"Giuseppe","family":"Daniele","sequence":"first","affiliation":[{"name":"Department of Medicine, Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deidre","family":"Winnier","sequence":"additional","affiliation":[{"name":"Department of Medicine, Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mari","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience, National Research Council, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bruder","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Fourcaudot","sequence":"additional","affiliation":[{"name":"Department of Medicine, Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuo","family":"Pengou","sequence":"additional","affiliation":[{"name":"Department of Medicine, Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devjit","family":"Tripathy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Jenkinson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Folli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, TX"},{"name":"Departamento de Clinica Medica, Faculdade de Ciencias Medicas, Obesity and Comorbidities Research Center, Universidade Estadual de Campinas, Campinas, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2015,6,18]]},"reference":[{"key":"2022031221002919900_B1","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.2337\/dc14-1036","article-title":"The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes","volume":"37","author":"Dall","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031221002919900_B2"},{"key":"2022031221002919900_B3","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2337\/db05-1200","article-title":"Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study","volume":"55","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes"},{"key":"2022031221002919900_B4","doi-asserted-by":"crossref","first-page":"12490","DOI":"10.1073\/pnas.93.22.12490","article-title":"Cross-talk between the insulin and angiotensin signaling systems","volume":"93","author":"Velloso","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022031221002919900_B5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1056\/NEJM198708063170605","article-title":"Insulin resistance in essential hypertension","volume":"317","author":"Ferrannini","year":"1987","journal-title":"N Engl J Med"},{"key":"2022031221002919900_B6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1474-9726.2010.00642.x","article-title":"At the crossroads of longevity and metabolism: the metabolic syndrome and lifespan determinant pathways","volume":"10","author":"Fadini","year":"2011","journal-title":"Aging Cell"},{"key":"2022031221002919900_B7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2215\/CJN.07891109","article-title":"Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes","volume":"5","author":"Plantinga","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031221002919900_B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI72323","article-title":"Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation","volume":"124","author":"Wei","year":"2014","journal-title":"J Clin Invest"},{"key":"2022031221002919900_B9","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J"},{"key":"2022031221002919900_B10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cmet.2013.01.009","article-title":"LRP6 enhances glucose metabolism by promoting TCF7L2-dependent insulin receptor expression and IGF receptor stabilization in humans","volume":"17","author":"Singh","year":"2013","journal-title":"Cell Metab"},{"key":"2022031221002919900_B11","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1126\/science.1136370","article-title":"LRP6 mutation in a family with early coronary disease and metabolic risk factors","volume":"315","author":"Mani","year":"2007","journal-title":"Science"},{"key":"2022031221002919900_B12","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc14-S014","article-title":"Standards of medical care in diabetes\u20142014","volume":"37","author":"American Diabetes Association","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031221002919900_B13","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.2337\/diabetes.51.2007.S221","article-title":"Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation","volume":"51","author":"Mari","year":"2002","journal-title":"Diabetes"},{"key":"2022031221002919900_B14","doi-asserted-by":"crossref","first-page":"E1159","DOI":"10.1152\/ajpendo.00093.2002","article-title":"Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects","volume":"283","author":"Mari","year":"2002","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031221002919900_B15","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2337\/diabetes.41.3.368","article-title":"Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance","volume":"41","author":"Van Cauter","year":"1992","journal-title":"Diabetes"},{"key":"2022031221002919900_B16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2337\/diabetes.50.1.150","article-title":"Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity","volume":"50","author":"Breda","year":"2001","journal-title":"Diabetes"},{"key":"2022031221002919900_B17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1749-6632.1959.tb44923.x","article-title":"Influences of glucose loading and of injected insulin on hepatic glucose output","volume":"82","author":"Steele","year":"1959","journal-title":"Ann N Y Acad Sci"},{"key":"2022031221002919900_B18","doi-asserted-by":"crossref","first-page":"ra6","DOI":"10.1126\/scisignal.2001249","article-title":"Wnt signaling regulates hepatic metabolism","volume":"4","author":"Liu","year":"2011","journal-title":"Sci Signal"},{"key":"2022031221002919900_B19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00774-013-0524-z","article-title":"Effect of liver dysfunction on circulating sclerostin","volume":"32","author":"Rhee","year":"2014","journal-title":"J Bone Miner Metab"},{"key":"2022031221002919900_B20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1172\/JCI113338","article-title":"Quantitative study of insulin secretion and clearance in normal and obese subjects","volume":"81","author":"Polonsky","year":"1988","journal-title":"J Clin Invest"},{"key":"2022031221002919900_B21","first-page":"E349","article-title":"Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans","volume":"254","author":"Tillil","year":"1988","journal-title":"Am J Physiol"},{"key":"2022031221002919900_B22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature13297","article-title":"Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones","volume":"511","author":"Maianti","year":"2014","journal-title":"Nature"},{"key":"2022031221002919900_B23","first-page":"608","article-title":"Insulin degradation: progress and potential","volume":"19","author":"Duckworth","year":"1998","journal-title":"Endocr Rev"},{"key":"2022031221002919900_B24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0026-0495(83)90004-5","article-title":"Decreased hepatic insulin extraction in subjects with mild glucose intolerance","volume":"32","author":"Bonora","year":"1983","journal-title":"Metabolism"},{"key":"2022031221002919900_B25","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1172\/JCI112758","article-title":"Splanchnic insulin metabolism in obesity. Influence of body fat distribution","volume":"78","author":"Peiris","year":"1986","journal-title":"J Clin Invest"},{"key":"2022031221002919900_B26","first-page":"144","article-title":"Decreased insulin clearance as a feature of essential hypertension","volume":"74","author":"Salvatore","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221002919900_B27"},{"key":"2022031221002919900_B28","doi-asserted-by":"crossref","first-page":"E501","DOI":"10.1152\/ajpendo.2000.278.3.E501","article-title":"Roles of insulin resistance and obesity in regulation of plasma insulin concentrations","volume":"278","author":"Jones","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031221002919900_B29","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.2337\/diabetes.49.12.2116","article-title":"Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response","volume":"49","author":"Mittelman","year":"2000","journal-title":"Diabetes"},{"key":"2022031221002919900_B30"},{"key":"2022031221002919900_B31","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1210\/jc.2012-1901","article-title":"Sclerostin levels associated with inhibition of the Wnt\/\u03b2-catenin signaling and reduced bone turnover in type 2 diabetes mellitus","volume":"97","author":"Gaudio","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221002919900_B32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/jc.2011-2186","article-title":"Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus","volume":"97","author":"Garc\u00eda-Mart\u00edn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221002919900_B33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/cen.12364","article-title":"Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus","volume":"80","author":"Neumann","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2022031221002919900_B34","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.2337\/dc12-1691","article-title":"Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels","volume":"36","author":"Morales-Santana","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031221002919900_B35"},{"key":"2022031221002919900_B36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2106\/JBJS.N.00654","article-title":"Sclerostin antibody treatment improves implant fixation in a model of severe osteoporosis","volume":"97","author":"Virdi","year":"2015","journal-title":"J Bone Joint Surg Am"},{"key":"2022031221002919900_B37","doi-asserted-by":"crossref","first-page":"E503","DOI":"10.1210\/jc.2012-3416","article-title":"Characterization of the Wnt inhibitors secreted frizzled-related proteins (SFRPs) in human adipose tissue","volume":"98","author":"Ehrlund","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221002919900_B38","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00125-013-2976-z","article-title":"Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study","volume":"56","author":"Tripathy","year":"2013","journal-title":"Diabetologia"},{"key":"2022031221002919900_B39","doi-asserted-by":"crossref","first-page":"E1473","DOI":"10.1210\/jc.2012-1218","article-title":"Association of circulating sclerostin levels with fat mass and metabolic disease\u2014related markers in Japanese postmenopausal women","volume":"97","author":"Urano","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221002919900_B40","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jgs.12791","article-title":"Sclerostin in institutionalized elderly women: associations with quantitative bone ultrasound, bone turnover, fractures, and mortality","volume":"62","author":"Amrein","year":"2014","journal-title":"J Am Geriatr Soc"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/8\/1509\/624568\/dc142989.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/8\/1509\/624568\/dc142989.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T18:05:21Z","timestamp":1647108321000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/38\/8\/1509\/31308\/Sclerostin-and-Insulin-Resistance-in-Prediabetes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,18]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,6,18]]},"published-print":{"date-parts":[[2015,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc14-2989","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,18]]}}}